VIP 943
Alternative Names: BAY-943; IL3RA-KSPi-ADC; VIP-943Latest Information Update: 10 Oct 2024
At a glance
- Originator Bayer
- Developer Vincerx Pharma
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action KIF11 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; B-cell lymphoma; Myelodysplastic syndromes
Most Recent Events
- 07 Oct 2024 Efficacy, adverse events, pharmacokinetic and pharmacodynamics data from a phase I trial in B-cell lymphoma, Acute myeloid leukaemia and Myelodysplastic syndromes released by Vincerx Pharma
- 08 Apr 2024 Adverse events and pharmacokinetic data from a phase I trial in B-cell lymphoma, Acute myeloid leukaemia and Myelodysplastic syndromes released by Vincerx Pharma
- 05 Apr 2024 Pharmacodynamics from a preclinical trial in Acute myeloid leukemia presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024 2024)